← Leaderboards
Eric L Nuermberger
Johns Hopkins University
$20,859,483
Attributed
$35,324,093
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,324,093 · 12
By mechanism
UM1$14,399,999 · 1
R01$13,009,859 · 4
U19$2,969,622 · 1
R33$1,778,326 · 1
R61$1,723,189 · 1
K08$622,620 · 1
Top collaborators
- Kelly E. Dooley7 shared
- Craig A Townsend5 shared
- Radojka Savic2 shared
- Dirk Schnappinger2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Ying Zhang$6,675,418
- Jacques H. Grosset$1,997,313
- Alfredo Jose Guerra$157,172
- William W Eaton$22,660,492
- Richard E Chaisson$50,014,616
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisPharmaceutical PreparationsDoseRegimenTuberculosis TreatmentMouse ModelMycobacterium TuberculosisPharmacodynamicsIn VitroTuberculosis DrugsPreventPre-ClinicalBaseResistanceTreatment ProtocolsClinical TrialsCollaborationsInnovationDrug ResistanceNovel TherapeuticsPreventionDrug DevelopmentDrug Resistance In TuberculosisOral
Grant awards (40)
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium$7,200,000
UM1 · FY2025 · AI
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis$1,073,841
R33 · FY2025 · AI · contact PI
Pharmacology and Pharmacometrics Core$129,210
P30 · FY2025 · AI · contact PI
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium$7,199,999
UM1 · FY2024 · AI
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis$704,485
R33 · FY2024 · AI · contact PI
Pharmacology and Pharmacometrics Core$113,866
P30 · FY2024 · AI · contact PI
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis$617,725
R61 · FY2023 · AI · contact PI
JHU- Optimal regimen development on a Ribosome inhibitor backbone.$546,375
U19 · FY2023 · AI · contact PI
Pharmacology and Pharmacometrics Core$127,276
P30 · FY2023 · AI · contact PI
JHU- Optimal regimen development on a Ribosome inhibitor backbone.$850,915
U19 · FY2022 · AI · contact PI
Development of novel penems for drug-resistant tuberculosis$745,773
R01 · FY2022 · AI
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis$631,159
R61 · FY2022 · AI · contact PI
Development of novel penems for drug-resistant tuberculosis$759,045
R01 · FY2021 · AI
JHU- Optimal regimen development on a Ribosome inhibitor backbone.$542,407
U19 · FY2021 · AI · contact PI
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis$474,305
R61 · FY2021 · AI · contact PI
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention$853,989
R01 · FY2020 · AI · contact PI
Development of novel penems for drug-resistant tuberculosis$773,080
R01 · FY2020 · AI
JHU- Optimal regimen development on a Ribosome inhibitor backbone.$505,143
U19 · FY2020 · AI · contact PI
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention$866,149
R01 · FY2019 · AI · contact PI
Development of novel penems for drug-resistant tuberculosis$792,429
R01 · FY2019 · AI
JHU- Optimal regimen development on a Ribosome inhibitor backbone.$524,782
U19 · FY2019 · AI · contact PI
Exploiting a robust drug discovery portfolio to develop effective regimens to treat Mycobacterium abscessus lung infection$204,688
R21 · FY2019 · AI · contact PI
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention$881,258
R01 · FY2018 · AI · contact PI
Development of novel penems for drug-resistant tuberculosis$804,846
R01 · FY2018 · AI
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$718,961
R01 · FY2018 · AI · contact PI
Exploiting a robust drug discovery portfolio to develop effective regimens to treat Mycobacterium abscessus lung infection$245,438
R21 · FY2018 · AI · contact PI
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention$895,058
R01 · FY2017 · AI · contact PI
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$748,871
R01 · FY2017 · AI · contact PI
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention$945,739
R01 · FY2016 · AI · contact PI
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$668,698
R01 · FY2016 · AI · contact PI
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$657,921
R01 · FY2015 · AI · contact PI
Integrative Pharmacology Approach to Understand Mechanisms of TB Drug Resistance$659,598
R01 · FY2014 · AI · contact PI
Advancing New Drug Regimens for MDR/XDR TB$426,972
R01 · FY2012 · AI · contact PI
Advancing New Drug Regimens for MDR/XDR TB$421,718
R01 · FY2011 · AI · contact PI
Advancing New Drug Regimens for MDR/XDR TB$389,754
R01 · FY2010 · AI · contact PI
Defining Moxifloxacin as a First-line TB Drug$129,330
K08 · FY2008 · AI · contact PI
Defining Moxifloxacin as a First-line TB Drug$129,330
K08 · FY2007 · AI · contact PI
Defining Moxifloxacin as a First-line TB Drug$129,330
K08 · FY2006 · AI · contact PI
Defining Moxifloxacin as a First-line TB Drug$117,720
K08 · FY2005 · AI
Defining Moxifloxacin as a First-line TB Drug$116,910
K08 · FY2004 · AI